{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:18:42Z","timestamp":1793146722849,"version":"4.5.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"\n Importance<\/jats:title>\n Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed immune thrombocytopenia treated with eltrombopag than in those treated with standard therapy (first-line treatments).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This phase 3, randomized clinical trial enrolled patients (aged 1-&amp;lt;18 years) with newly diagnosed primary immune thrombocytopenia (platelet count &amp;lt;30\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/L who required pharmacological treatment but did not have severe bleeding or need a rapid increase in platelet count) from May 7, 2019, to January 25, 2024, at 23 centers participating in the Pediatric ITP Consortium of North America. Final follow-up occurred on February 26, 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Eltrombopag was administered orally based on a standard dosing schedule (n\u2009=\u200978) vs standard therapy (investigator choice of glucocorticoids, intravenous immunoglobulin, or anti-D immunoglobulin) (n\u2009=\u200940).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcome was a sustained platelet response defined as 3 or more of 4 platelet counts greater than 50\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/L during weeks 6 to 12 without rescue treatment. The secondary outcomes included bleeding scores, change in health-related quality of life, and serious adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 118 pediatric patients (median age, 8 years [IQR, 4-12 years]; 49% were male), 63% experienced an initial treatment failure after observation or medical therapy. Enrollment ended after a planned interim analysis met a prespecified threshold for efficacy. Of 71 patients in the eltrombopag group, 46 (65% [95% CI, 54%-76%]) had a sustained platelet response compared with 13 of 37 patients (35% [95% CI, 20%-51%]) in the standard therapy group (between-group difference, 30% [95% CI, 11%-49%];\n P<\/jats:italic>\n \u2009=\u2009.002), which crossed the monitoring boundary for efficacy. Overall, there was no between-group difference in the number and type of adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In pediatric patients with newly diagnosed immune thrombocytopenia requiring pharmacological treatment, eltrombopag resulted in a higher rate of sustained platelet response compared with standard therapy. Eltrombopag may be an effective option for pediatric patients with newly diagnosed immune thrombocytopenia with nonsevere bleeding who warrant medical intervention.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03939637<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.18168","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:31:02Z","timestamp":1761147062000},"page":"1816","source":"Crossref","is-referenced-by-count":8,"title":["Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment"],"prefix":"10.1001","volume":"334","author":[{"given":"Kristin A.","family":"Shimano","sequence":"first","affiliation":[{"name":"UCSF Benioff Children\u2019s Hospitals, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Grimes","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Center, Houston"},{"name":"Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Kaicker","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine\/NewYork Presbyterian-Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders, Phoenix Children\u2019s Hospital, Phoenix, Arizona"},{"name":"Department of Child Health, College of Medicine, University of Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gunn","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"},{"name":"Department of Pediatrics, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhmi V.","family":"Bhat","sequence":"additional","affiliation":[{"name":"Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"},{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Kochhar","sequence":"additional","affiliation":[{"name":"Hasbro Children\u2019s Hospital, Providence, Rhode Island"},{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Rothman","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Rose","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"},{"name":"College of Medicine, Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Briones","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo A.","family":"Nakano","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Lebensburger","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Lambert","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Fritch Lilla","sequence":"additional","affiliation":[{"name":"Children\u2019s Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohith","family":"Jesudas","sequence":"additional","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy A.","family":"Lee-Miller","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Wisconsin, Madison"},{"name":"American Family Children\u2019s Hospital, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Rifkin-Zenenberg","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvankar","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Children\u2019s National Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley E.","family":"Crary","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Hege","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children, Indianapolis, Indiana"},{"name":"School of Medicine, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Ford","sequence":"additional","affiliation":[{"name":"Primary Children\u2019s Hospital, Salt Lake City, Utah"},{"name":"School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Bies","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fort","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung T.","family":"Wynn","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loan","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Health, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza E.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Health, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Dinu","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Center, Houston"},{"name":"Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M. W.","family":"Wong","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, Massachusetts"},{"name":"Broad Institute, Cambridge, Massachusetts"},{"name":"Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chi","family":"Kao","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor O.","family":"Kim","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Los Angeles, California"},{"name":"Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci D.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Pharmaceutical Systems Inc Contract Research Organization (PSI CRO), King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Despotovic","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Klaassen","sequence":"additional","affiliation":[{"name":"CHEO (Children\u2019s Hospital of Eastern Ontario) Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis J.","family":"Neufeld","sequence":"additional","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy E.","family":"Neunert","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Morgan Stanley Children\u2019s Hospital, New York, New York"},{"name":"Irving Medical Center, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy B.","family":"London","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"joi250081r1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports.","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"issue":"6","key":"joi250081r2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia.","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"joi250081r3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"issue":"3","key":"joi250081r4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"joi250081r5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.16751","article-title":"Fatigue in children and adolescents with immune thrombocytopenia.","volume":"191","author":"Grace","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"joi250081r6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3324\/haematol.2014.106963","article-title":"Health-related quality of life in children with newly diagnosed immune thrombocytopenia.","volume":"99","author":"Heitink-Poll\u00e9","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"joi250081r7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/pbc.20453","article-title":"Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS).","volume":"46","author":"Imbach","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"joi250081r8","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia.","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"joi250081r9","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia.","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"joi250081r10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.","volume":"132","author":"Heitink-Poll\u00e9","year":"2018","journal-title":"Blood"},{"issue":"6","key":"joi250081r11","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12592","article-title":"Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern.","volume":"5","author":"Cuker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"joi250081r12","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1182\/bloodadvances.2019001343","article-title":"IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.","volume":"4","author":"Carcao","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"joi250081r13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/s-0039-1684031","article-title":"First-line therapy for immune thrombocytopenia.","volume":"39","author":"Mithoowani","year":"2019","journal-title":"Hamostaseologie"},{"issue":"12","key":"joi250081r14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/medicina56120667","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management.","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina (Kaunas)"},{"issue":"10004","key":"joi250081r15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"joi250081r16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044885","article-title":"Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol.","volume":"11","author":"Shimano","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"joi250081r17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1067\/mpd.2002.128547","article-title":"Grading of hemorrhage in children with idiopathic thrombocytopenic purpura.","volume":"141","author":"Buchanan","year":"2002","journal-title":"J Pediatr"},{"issue":"11","key":"joi250081r18","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"5","key":"joi250081r19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jpeds.2007.01.037","article-title":"Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids\u2019 ITP Tools.","volume":"150","author":"Klaassen","year":"2007","journal-title":"J Pediatr"},{"issue":"5","key":"joi250081r20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"issue":"2","key":"joi250081r21","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure.","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"issue":"10","key":"joi250081r22","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2008-03-138487","article-title":"Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.","volume":"112","author":"Neunert","year":"2008","journal-title":"Blood"},{"issue":"22","key":"joi250081r23","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","article-title":"Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS).","volume":"121","author":"Neunert","year":"2013","journal-title":"Blood"},{"issue":"1","key":"joi250081r24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/pbc.24257","article-title":"Quality of life in childhood immune thrombocytopenia: international validation of the Kids\u2019 ITP Tools.","volume":"60","author":"Klaassen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"joi250081r25","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"issue":"8","key":"joi250081r26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/00043426-200308000-00017","article-title":"Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis.","volume":"25","author":"Butros","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"joi250081r27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/jth.13019","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: reply.","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"13","key":"joi250081r28","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1182\/bloodadvances.2024015494","article-title":"Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study.","volume":"9","author":"Sirotich","year":"2025","journal-title":"Blood Adv"},{"issue":"25","key":"joi250081r29","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1182\/blood-2014-01-549360","article-title":"Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.","volume":"123","author":"G\u00f3mez-Almaguer","year":"2014","journal-title":"Blood"},{"issue":"4","key":"joi250081r30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12185-014-1533-y","article-title":"Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.","volume":"99","author":"Tripathi","year":"2014","journal-title":"Int J Hematol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2840458\/jama_shimano_2025_oi_250081_1763752232.99194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:00:38Z","timestamp":1764086438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2840458"}},"subtitle":["The PINES Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.18168","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}